Investorideas.com

Call 800 665 0411 to learn about our services

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS



Share on StockTwits

Biotech Stock News: IVRO (OTC PINK: IVRO) with a Mission to Help Make Non-Animal Testing Famous, Releases Fiscal Q2 2022 Results

 

Placentia, California - April 26, 2022 (Newsfile Corp.) (Investorideas.com Newswire) InVitro International (OTC PINK: IVRO), an established leader in advancing NON-Animal testing technologies, today announced fiscal 2022 year to date and second fiscal quarter financial results. Second quarter sales of $260,219 were up 27% over the same quarter last year; this increased year to date sales to $443,780, now 9.2% ahead of fiscal 2021 sales for the first half. Second quarter suffered a net loss of $24,636 due in large part to a GAAP recent change in reporting unrealized investment gains and losses within a quarter, no longer at the end of the year. Despite this change, our second quarter loss was an improvement of 57% over the same period last year; and our year to date fiscal 2022 net income is a positive $32,303, up 220% from last year. Both fiscal years benefited from PPP's as previously reported.

In describing 1st half results, CEO W. Richard Ulmer said: "IVRO's message is being received well by more laboratories and companies. Recently our core technology was recognized as having met the world's highest regulatory and scientific standards via OECD adoption covering 37 countries, including the U.S. Although it took more than a decade to achieve this goal, we now have the credibility necessary to help new formulations and products reach their markets faster, at lower development costs, with complete confidence & added kindness to animals. More than ever, IVRO views NON-Animal testing as a growth market opportunity thanks to government support, and increased general population awareness. In the U.S., the Humane Cosmetics Act of '21 is now on the floors of Congress, after several years in Committee. Our primary goal remains to accelerate the global shift toward using fewer animals in human safety testing."

InVitro International President, Atul Jhalani, added: "When speaking with partner laboratories as well as companies which have not yet begun to use NON-Animal test technologies, we find increased support for the field and greater emphasis on the importance of OECD adoption of our technology. This bodes well for both animals and our business as the world returns to pre- pandemic conditions. May the movement continue!"

To be added to the Company's email list please click this link or for additional information, please call our investor relations department at 323-380-4500.

About InVitro International, Inc.

InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company's testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.

This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward looking statements. These risks and uncertainties include but are not limited to: acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward- looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.

Company Contact:

W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com
www.invitrointl.com

More Info:

Investorideas.com Newswire

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders


Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp


Follow Us on StockTwits






BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks

BiotechIndustryStocks.com - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on Investorideas.com